Felicitas E. Hengel , Michelle C.Z. Chong , Wing Yin Leung , Silke Dehde , Anne Mühlig , Matthias Janneck , Henry H.L. Wu , Tobias B. Huber , Arvind Ponnusamy , Nicola M. Tomas
{"title":"Non-invasive Diagnosis of Antinephrin–Associated Podocytopathy","authors":"Felicitas E. Hengel , Michelle C.Z. Chong , Wing Yin Leung , Silke Dehde , Anne Mühlig , Matthias Janneck , Henry H.L. Wu , Tobias B. Huber , Arvind Ponnusamy , Nicola M. Tomas","doi":"10.1016/j.ekir.2025.05.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Circulating autoantibodies against the podocyte surface protein nephrin have recently been described in patients with podocytopathies, that is, minimal change disease, primary focal segmental glomerulosclerosis, and childhood idiopathic nephrotic syndrome. Their high specificity for podocytopathies in combination with a strong correlation with disease activity hold the potential for a non-invasive diagnosis, but prospective data are lacking.</div></div><div><h3>Methods</h3><div>Here, we describe 3 patients with contraindications or unwillingness for a kidney biopsy, hampering a timely histological diagnosis and choice of appropriate therapy.</div></div><div><h3>Results</h3><div>In all patients, antinephrin autoantibodies were detected by quantitative immunoprecipitation, prompting the initiation of adequate treatment. These interventions induced a decrease in antinephrin autoantibody levels and clinical remission.</div></div><div><h3>Conclusion</h3><div>Our study highlights the potential of antinephrin autoantibody measurement for a noninvasive diagnosis of antinephrin-associated podocytopathy.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2800-2804"},"PeriodicalIF":5.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney International Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S246802492500292X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Circulating autoantibodies against the podocyte surface protein nephrin have recently been described in patients with podocytopathies, that is, minimal change disease, primary focal segmental glomerulosclerosis, and childhood idiopathic nephrotic syndrome. Their high specificity for podocytopathies in combination with a strong correlation with disease activity hold the potential for a non-invasive diagnosis, but prospective data are lacking.
Methods
Here, we describe 3 patients with contraindications or unwillingness for a kidney biopsy, hampering a timely histological diagnosis and choice of appropriate therapy.
Results
In all patients, antinephrin autoantibodies were detected by quantitative immunoprecipitation, prompting the initiation of adequate treatment. These interventions induced a decrease in antinephrin autoantibody levels and clinical remission.
Conclusion
Our study highlights the potential of antinephrin autoantibody measurement for a noninvasive diagnosis of antinephrin-associated podocytopathy.
期刊介绍:
Kidney International Reports, an official journal of the International Society of Nephrology, is a peer-reviewed, open access journal devoted to the publication of leading research and developments related to kidney disease. With the primary aim of contributing to improved care of patients with kidney disease, the journal will publish original clinical and select translational articles and educational content related to the pathogenesis, evaluation and management of acute and chronic kidney disease, end stage renal disease (including transplantation), acid-base, fluid and electrolyte disturbances and hypertension. Of particular interest are submissions related to clinical trials, epidemiology, systematic reviews (including meta-analyses) and outcomes research. The journal will also provide a platform for wider dissemination of national and regional guidelines as well as consensus meeting reports.